Gilead ponders Sovaldi price break

Share this article:

Antiviral drugmaker Gilead is rumored to be in price negotiations in India for its new hep. C pill Sovaldi (sofosbuvir). The Hindu Business Line reports that the biotech is looking to introduce Sovaldi into India's marketplace.

Twelve weeks of the treatment costs $84,000 in the US, but the framework for a deal in India is far different: the company is said to be looking to price its locally produced version of the medication at around $2,000 for six months of therapy. The company is in talks with patient advocacy groups.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

DOJ closes Brilinta investigation

AstraZeneca announced the end of the investigation Tuesday.

Doctors back unique biosimilar names

A host of doctors has asked FDA Commissioner Margaret Hamburg to back a naming convention that would require biologics and biosimilars to have different names.

Roche has no rights to Sovaldi, panel rules

Despite a collaboration with original Sovaldi owner Pharmasset in 2004, a panel ruled Roche has no rights to HCV treatment Sovaldi.